Ruben Mesa, M.D.,Rami S. Komrokji, M.D. Experts Rami Komrokji, MD, and Ruben Mesa, MD, define myeloproliferative neoplasms (MPNs) and explain differences between ...

There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben ...

Key opinion leaders highlight different testing and workup methods involved in making an accurate diagnosis of myeloproliferative neoplasms. Ruben Mesa, M.D.: Rami (Rami Komrokji, M.D.), how would you ...

Please provide your email address to receive an email when new articles are posted on . “What I really took away from his presentation was just all of the ways that the inflammatory background of ...

This group of cancers remains a challenge to diagnose, can be rapidly progressive, and requires complex treatment and follow-up care, research suggests. Despite recent advancements in treatments for ...

—In a new study, revascularization reduced major adverse cardiovascular and limb events (MACLE) and amputations, but it increased bleeding and stroke risk, highlighting the need for careful risk ...

—According to a new U.S.-based study, pulmonary hypertension is associated with an increased risk of hematologic progression, adverse cardiovascular events, and all-cause mortality in patients with ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Andrew Tiu, MD, discussed results from a study regarding the link between Agent Orange ...

Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.

AUSTIN, Texas & MONTREAL--(BUSINESS WIRE)--Forbius, a clinical-stage company that develops biologics for the treatment of cancer and fibrosis, announced today a collaboration agreement with the Icahn ...

Researchers from Incyte Corp. and collaborators presented the preclinical profile of INCB-160058, an ATP-competitive small-molecule inhibitor of the JAK2 V617F mutant sparing its wild-type (WT) form, ...